39
IRUS Total
Downloads

Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.

File Description SizeFormat 
Review - Final version.docxAccepted version2.29 MBMicrosoft WordView/Open
biomedicines-05-00050.pdfPublished version4.56 MBAdobe PDFView/Open
Title: Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.
Authors: Begalli, F
Bennett, J
Capece, D
Verzella, D
D'Andrea, D
Tornatore, L
Franzoso, G
Item Type: Journal Article
Abstract: Transcription factors of the nuclear factor κB (NF-κB) family are central coordinating regulators of the host defence responses to stress, injury and infection. Aberrant NF-κB activation also contributes to the pathogenesis of some of the most common current threats to global human health, including chronic inflammatory diseases, autoimmune disorders, diabetes, vascular diseases and the majority of cancers. Accordingly, the NF-κB pathway is widely considered an attractive therapeutic target in a broad range of malignant and non-malignant diseases. Yet, despite the aggressive efforts by the pharmaceutical industry to develop a specific NF-κB inhibitor, none has been clinically approved, due to the dose-limiting toxicities associated with the global suppression of NF-κB. In this review, we summarise the main strategies historically adopted to therapeutically target the NF-κB pathway with an emphasis on oncology, and some of the emerging strategies and newer agents being developed to pharmacologically inhibit this pathway.
Issue Date: 22-Aug-2017
Date of Acceptance: 10-Aug-2017
URI: http://hdl.handle.net/10044/1/50398
DOI: https://dx.doi.org/10.3390/biomedicines5030050
ISSN: 2227-9059
Publisher: MDPI
Journal / Book Title: Biomedicines
Volume: 5
Issue: 3
Copyright Statement: © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Gadd45β
IκB kinase
NF-κB inhibitors
cancer
nuclear factor κB
ubiquitin
Publication Status: Published online
Article Number: 50
Appears in Collections:Department of Medicine (up to 2019)